Updates of colorectal cancer liver metastases therapy: review on DEBIRI | Zendy

Giammaria Fiorentini | Zendy; Donatella Sarti | Zendy; Roberto Nani | Zendy; Camillo Aliberti | Zendy; C Fiorentini | Zendy; Stefano Guadagni | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Updates of colorectal cancer liver metastases therapy: review on DEBIRI

Author(s) -

Giammaria Fiorentini,

Donatella Sarti,

Roberto Nani,

Camillo Aliberti,

C Fiorentini,

Stefano Guadagni

Publication year - 2020

Publication title -

hepatic oncology

Language(s) - English

Resource type - Journals

eISSN - 2045-0931

pISSN - 2045-0923

DOI - 10.2217/hep-2019-0010

Subject(s) - medicine , irinotecan , colorectal cancer , refractory (planetary science) , oncology , metastasis , chemotherapy , cancer , stage (stratigraphy) , liver cancer , paleontology , physics , astrobiology , biology

Colorectal cancer is a worldwide public health issue, presenting an advanced stage at diagnosis in more than 20% of patients. Liver metastases are the most common metastatic sites and are not indicated for resection in 80% of cases. Unresectable colorectal cancer liver metastases that are refractory to systemic chemotherapy may benefit from transarterial chembolization with irinotecan-loaded beads (DEBIRI). Several studies show the safety and efficacy of DEBIRI for the treatment of colorectal cancer liver metastases. The development of transarterial chembolization and the introduction of new embolics have contributed to better outcomes of DEBIRI. This article reviews the current literature on DEBIRI reporting its use, efficacy in terms of tumor response and survival and side effects.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research